Preoperative predictors for organ-confined disease in Japanese patients with stage T1c prostate cancer

International Journal of Urology

Volumn 5, Issue 5, 1998, Pages 454-458

  Ogawa, Osamu ^a   Egawa, Shin ^b   Arai, Yoichi ^c   Tobisu, Ken Ichi ^d   Yoshida, Osamu ^e   Kato, Tetsuro ^a  

^a AKITA UNIVERSITY   (Japan)

^b KITASATO UNIVERSITY   (Japan)

^c KURASHIKI CENTRAL HOSPITAL   (Japan)

^d NATIONAL CANCER CENTER HOSPITAL   (Japan)

^e KYOTO UNIVERSITY   (Japan)

Author keywords

Multivariate logistic regression analysis; Organ confined tumor; Prostate cancer; PSA; Stage T1c

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGE; AGED; ARTICLE; ASSAY; CANCER STAGING; CLINICAL FEATURE; HUMAN; LYMPH NODE; MAJOR CLINICAL STUDY; MALE; ORGAN SIZE; PREDICTION; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; REGRESSION ANALYSIS; SEMINAL VESICLE; TREATMENT PLANNING; TUMOR BIOPSY; TUMOR VOLUME;

EID: 0031768792     PISSN: 09198172     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1442-2042.1998.tb00387.x     Document Type: Article

References (23)

1. Catalona WJ, Smith DS, Ratliff T, Basler JW. Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening. JAMA 1993;270:948-954.
2. Oesterling JE, Suman VJ, Zincke H, Bostwick DG. PSA-detected (clinical stage T1c or BO) prostate cancer. Urol Clin N Am 1993;20:687-693.
3. Humphrey PA, Keetch DW, Smith DS, Shepherd DL, Catalona WJ. Prospective characterization of pathological features of prostatic carcinomas detected via serum prostate specific antigen based screening. J Urol 1996;155:816-820.
4. Nomura A, Kolone LN. Prostate cancer: a current perspective. Epidemiol Rev 1991;13:200-227.
5. Guileyardo JM, Johnson WD, Welsh RA, Akazaki K, Correa P. Prevalence of latent prostate carcinoma in two US populations. J Natl Cancer Inst 1980;65:311-316.
6. Yatani R, Shiraishi T, Nakakuki K, Kusano I, Takanari H, Hayashi T, Stemmermann GN. Trends in frequency of latent prostate carcinoma in Japan from 1965-1979 and 1982-1986. J Natl Cancer Inst 1988;80:683-687.
7. Yamabe H, Kate FJW, Gallee MPW, Schroeder FH, Oishi K, Okada K, Yoshida O. Stage A prostate cancer: a comparative study in Japan and the Netherlands. World J Urol 1986;4:136-140.
8. Machida T, Ohishi Y, Wada T, Akimoto S, Shimazaki J, Oda H, Yokoyama M, Tsukada T, Nakayama T, Akiyama A, Miki M, Meguro N, Usami M, Kotake T, Yamamoto M, Naito K. Clinical evaluation of a new kit (IMx PA Dinapak) for detection of human prostate specific antigen in the serum (in Japanese). Radioisotopes 1984;33:273-278.
9. Kuriyama M, Akimoto S, Akaza H, Arai Y, Usami M, Imai K, Tanaka Y, Yamazaki H, Kawada Y, Koiso K, Yoshida O, Kotake T, Yamanaka H, Machida T, Aso Y, Shimazaki J. Comparison of various assay systems for prostate-specific antigen standardization. Jpn J Clin Oncol 1992;22:393-399.
10. Greene DR, Wheeler TM, Egawa S, Dunn JK, Scardino PT. A comparison of the morphological features of cancer arising in the transition zone and in the peripheral zone of the prostate. J Urol 1991;146:1069-1076.
11. Epstein JI, Pizov G, Walsh PC. Correlation of pathologic findings with progression after radical retropubic prostatectomy. Cancer 1993;71:3582-3593.
12. Carter HB, Sauvageot J, Walsh PC, Epstein JI. Prospective evaluation of men with stage Tie adenocarcinoma of the prostate. J Urol 1997;157:2206-2209.
13. Epstein J, Walsh PC, Carmichael M, Brendler CB. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA 1994;270:368-374.
14. Soh S, Kattan MW, Berkman S, Wheeler TM, Scardino PT. Has there been a recent shift in the pathological features and prognosis of patients treated with radical prostatectomy? J Urol 1997;157:2212-2218.
15. Egawa S, Suyama K, Ohori M, Kawakami T, Kuwano S, Hirakado K, Hirano S, Yokoyama E, Uchida T, Koshiba K. Early detection of prostate cancer: results of a prostate specific antigen-based program in Japan. Cancer 1995;76:463-472.
16. Oesterling JE, Kumamoto Y, Tsukamoto T, Girman CJ, Masumori N, Jacobsen SJ, Lieber MM. Serum prostate-specific antigen in a community-based population of healthy Japanese men: lower values than for similarly aged white men. Br J Urol 1995;75:347-353.
17. Ohori M, Wheeler TM, Dunn JK, Stamey TA, Scardono PT. The pathologic features and prognosis of prostate cancer detectable with current diagnostic tests. J Urol 1994;152:1714-1720.
18. Scaletsky R, Koch MO, Eckstein CW, Bicknell SL, Gray GF Jr, Smith JA. Tumor volume and stage in carcinoma of the prostate detected by elevations in prostate specific antigen. J Urol 1994;152:129-131.
19. Partin AW, Kattan MW, Subong EN, Walsh PC, Wojno KJ, Oesterling JE, Scardino PT, Pearson JD. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. JAMA 1997;277:1445-1451.
20. Cookson MS, Fleshner NE, Soloway SM, Fair WR. Prognostic significance of prostate-specific antigen in stage T1c prostate cancer treated by radical prostatectomy. Urology 1997;49:887-893.
21. Partin AW, Yoo J, Carter HB, Pearson JD, Chan DW, Epstein JI, Walsh PC. The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol 1993;150:110-114.
22. Badalament RA, Miller MC, Peller PA, Young DC, Bahn DK, Kochie P, O'Dowd GJ, Veltri RW. An algorithm for predicting nonorgan confined prostate cancer using the results obtained from sextant biopsies with prostate specific antigen level. J Urol 1996;156:1375-1380.
23. Peller PA, Young DC, Marmaduke DP, Marsh WL, Balalament RA. Sextant prostate biopsies. A histopathologic correlation with radical prostatectomy specimens. Cancer 1995;75:530-538.